18F-FDG PET、PET/CT与PET/MRI对乳腺癌初始分期及管理的影响:系统综述与Meta分析
该系统综述与Meta分析纳入29项研究共4276例乳腺癌患者,评估18F-FDG PET、PET/CT和PET/MRI在初始分期中对分期和管理的影响。汇总结果显示,分期改变比例为25%(95%CI 21%-30%),管理改变比例为18%(95%CI 14%-23%)。现有文献提示PET显像可显著改变新诊断乳腺癌患者的分期和治疗。
要点
- 18F-FDG PET显像使25%乳腺癌患者分期改变,18%管理改变
- III期患者分期改变比例最高(34%),I期最低(11%)
- 结果支持PET显像用于乳腺癌初始分期的常规临床实践
核心结论
- 现有文献提示18F-FDG PET、PET/CT或PET/MRI可显著改变新诊断乳腺癌患者的分期与治疗。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Cochrane Library和KoreaMed至2020年3月,纳入29项研究共4276例患者。
主要发现
- 分期改变的汇总比例为25%(95%CI 21%-30%),管理改变的汇总比例为18%(95%CI 14%-23%)。
- 按初始分期分层,分期改变比例在I期为11%(95%CI 3%-22%),II期为20%(95%CI 16%-24%),III期为34%(95%CI 27%-42%)。
- 不同显像方式间改变和意向治疗改变的比例分别为74%和70%。
关键数值与推荐
- 采用随机效应模型汇总改变比例,并进行亚组分析和Meta回归探索异质性。
- Meta回归分析显示,平均年龄、初始III至IV期比例和组织学II至III级比例是影响分期或管理改变异质性的显著因素。
临床怎么用
- 对于新诊断乳腺癌患者,可考虑在初始分期中应用18F-FDG PET、PET/CT或PET/MRI以优化分期和治疗决策。
局限性
- 纳入研究间存在异质性,受平均年龄、初始分期分布和组织学分级等因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We performed a systematic review and meta-analysis to evaluate the impact of 18F-FDG PET, PET/CT, and PET/MRI on staging and management during the initial staging of breast cancer. METHODS: We searched the PubMed, Embase, Cochrane Library, and KoreaMed databases until March 2020 to identify studies that reported the proportion of breast cancer patients whose clinical stage or management were changed after PET scans. The proportion of changes was pooled using a random-effects model. Subgroup and metaregression analyses were performed to explore heterogeneity. RESULTS: We included 29 studies (4276 patients). The pooled proportions of changes in stage and management were 25% (95% confidence interval [CI], 21%-30%) and 18% (95% CI, 14%-23%), respectively. When stage changes were stratified according to initial stage, the pooled proportions were 11% (95% CI, 3%-22%) in stage I, 20% (95% CI, 16%-24%) in stage II, and 34% (95% CI, 27%-42%) in stage III. The relative proportions of intermodality and intention-to-treat changes were 74% and 70%, respectively. Using metaregression analyses, the mean age and the proportion of initial stage III to IV and histologic grade II to III were significant factors affecting the heterogeneity in changes in stage or management. CONCLUSIONS: Currently available literature suggests that the use of 18F-FDG PET, PET/CT, or PET/MRI leads to significant modification of staging and treatment in newly diagnosed breast cancer patients. Therefore, there may be a role for routine clinical use of PET imaging for the initial staging of breast cancer.
引用
- Han S, Choi JY. Impact of 18F-FDG PET, PET/CT, and PET/MRI on Staging and Management as an Initial Staging Modality in Breast Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med. 2021. PMID: 33651022. doi:10.1097/RLU.0000000000003502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。